Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00823654 · ClinicalTrials.gov registry record

Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

A clinical trial of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
609
Enrollment target
8
Study locations

NCT00823654: Recruiting study of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00823654 is a study of Breast Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 609 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (78% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00823654, a study of Breast Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
609 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to learn more about the effects of your BRCA mutation on the ovaries. The BRCA gene can make it hard to conceive a child in the future. It may also bring on early menopause. The researchers will check blood levels of hormones that the ovaries produce. The hormones that researchers will check are anti-Mullerian hormone (AMH), estradiol and follicle stimulating hormone (FSH). The researchers will do this before, during, and after cancer treatment. The researchers will also ask you to fill out questionnaires about your menstrual cycle (your periods) and information about your health and pregnancies. This may help us learn which women will be more likely to have early menopause.

Primary Outcome

in premenopausal breast cancer patients \& to characterize the changes in serum AMH from baseline to 1 year in unaffected high risk BRCA mutation carriers.

Conditions Studied

Interventions

  • OTHER Blood draw and questionnaires

Study Locations (8)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • New York Presbyterian Hospital-Weill Medical College of Cornell University - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Trial Details

FieldValue
Enrollment Target 609 participants
Start Date 2009-01
Est. Completion 2027-01
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT00823654 shows while recruiting

NCT00823654 is an observational study that tracks outcomes without assigning an intervention. The registered 609 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood draw and questionnaires is the first listed.

NCT00823654 lists 8 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT00823654 about?

NCT00823654 is a clinical study titled "Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations". The purpose of this study is to learn more about the effects of your BRCA mutation on the ovaries. The BRCA gene can make it hard to conceive a child in the future. It may also bring on early menopause. The researchers will check blood levels of hormones that the ovaries produce. The hormones that r...

What is the current status of trial NCT00823654?

This trial is currently recruiting. The enrollment target is 609 participants. The study started on 2009-01. Estimated completion is 2027-01.

What conditions does trial NCT00823654 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00823654?

The interventions under investigation include: Blood draw and questionnaires (OTHER).

Who is sponsoring clinical trial NCT00823654?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00823654 being conducted?

This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00823654's enrollment target sits among peer trials

609 173rd of 1224 higher than 1,052 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03536312 · 610 participants · NA

    Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

  • NCT05838638 · 610 participants · NA

    Serious Gaming for Chemotherapy-induced Nausea and Vomiting

  • NCT07075718 · 610 participants · Phase 2

    Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

  • NCT02064673 · 608 participants · Phase 3

    Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00823654, the US trial registry maintained by the National Library of Medicine. NCT00823654 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.